Skip Navigation

Cardiovascular Research 2004 63(4):739-746; doi:10.1016/j.cardiores.2004.05.015
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fresco, P.
Right arrow Articles by Gonçalves, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fresco, P.
Right arrow Articles by Gonçalves, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

Facilitation of noradrenaline release by activation of adenosine A2A receptors triggers both phospholipase C and adenylate cyclase pathways in rat tail artery

Paula Fresco, Carmen Diniz and Jorge Gonçalves*

Serviço de Farmacologia, CEQOFF/FCT, Faculdade de Farmácia, Universidade do Porto, Rua Aníbal Cunha, 164, P 4050-047 Porto, Portugal

* Corresponding author. Tel.: +351-222078932; fax: +351-222078969. Email address: jorge.goncalves{at}ff.up.pt

Objective: The present work is aimed at elucidating the signalling pathway(s) triggered by activation of A2A receptors involved in the facilitation of noradrenaline release in rat tail artery as an attempt to clarify their role in the cardiovascular system. Methods: Electrically evoked (5 Hz, 100 pulses, 1 ms) tritium overflow was evaluated in preparations of rat tail artery, pre-incubated with [3H]-noradrenaline (0.1 µM), in the absence or in the presence of adenosine receptor agonists and antagonists and/or activators and inhibitors of phospholipase C (PLC)-protein kinase C (PKC) and of adenylate cyclase (AC)-cyclic adenosine-3',5'-monophosphate (cAMP)-protein kinase A (PKA) pathways. Results: Activation of A2A receptors by 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS 21680; 100 nM) enhanced tritium overflow, an effect prevented by the A2A receptor antagonist 5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo-[4,3]-1,2,4-triazolo[1,5]pyrimidine (SCH 58261; 20 nM), by the protein kinase A (PKA) inhibitor N-(2-[p-bromocinnamylamino]ethyl)-5-isoquinolinesulfonamide (H-89; 1 µM), or the PKC inhibitor 2-(8-[(dimethylamino)methyl-6,7,8,9-tetrahydropyrido[1,2]indol-3-yl]-3-(1-methylindol-3-yl)maleimide (Ro 32-0432; 1 µM). The PKC activator phorbol 12-myristate 13-acetate (PMA; 1 µM) and the PKA activator 8-bromo-cAMP (0.5 mM) also enhanced tritium overflow. The effect caused by PMA was blunted both by Ro 32-0432 and by H-89 whereas that caused by 8-bromo-cAMP was only prevented by H-89. Conclusions: In rat tail artery, the A2A receptor-mediated facilitation of noradrenaline release requires activation of both PKC and PKA, and PKA activation seems to occur downstream of PKC activation.

KEYWORDS Adenosine; Receptors; Protein kinase C; Protein kinase A; Signal transduction

Time for primary review 20 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.